Vesper Bio

Vesper Bio is attending the 43rd Annual J.P. Morgan Healthcare Conference on January 13-16, 2025 in San Francisco, CA. Paul Little, CEO; Mads Fuglsang Kjolby, Co-founder & iCMO; Anders Nykjaer, Co-Founder & CSO, and Andy Mulvaney, PhD, iCBO, will be attending as part of the Vesper team and are looking forward to connecting with the global life sciences community. Get in touch if you would like to meet during the JPM Week to learn more about our lead candidate #VES001 for frontotemporal dementia (FTD) and the rest of our groundbreaking pipeline of first-in-class small molecule #sortilin inhibitors. #JPMorgan #Neurodegeneration

Read Vesper Bio CEO Paul Little's thoughts on the 'London Life Sciences Week' in pharmaphorum's recent roundup article. The article captures the growing ambition surrounding the event with, as Paul says, 'a strong desire to have this conference grow and mature as a European hub for deal making.' Article credit: Richard Staines Link: https://lnkd.in/eYyKSTq3 #biotech #healthcare

This week, Vesper Bio's Director of Business Development, Lovisa Sunesson, will be presenting at the BioStock - Connecting Innovation and Capital, Life Science Summit from 20 - 21 November in Lund, Sweden.   📅Thursday, 21 November |🕔14:00 CET |📍Auditorium at Medicon Village   If you are also in Lund this week, make sure to come along to Lovisa's company presentation, where you can learn more about Vesper Bio’s groundbreaking pipeline of first-in-class small molecule #sortilin inhibitors, including #VES001, our lead candidate for frontotemporal dementia (FTD).   #BioStockSummit #BioStockSummit2024 #Neurodegeneration

Counting down the days until Vesper Bio will be joining the global biotech community for London Life Sciences Week (LLSW), November 18 - 21! Our CEO Paul Little will be attending the Jefferies London Healthcare Conference and is looking forward to connecting. If you are interested in learning about our groundbreaking work in #sortilin biology for the treatment of frontotemporal dementia (#FTD), get in touch! #LLSW #Jefferies #Biotech

Biotech company Vesper Bio announced in early September that its experimental treatment for #FTD #GRN successfully concluded a phase 1 trial. The company has applied to begin phase 2a studies with the drug VES001. Click here to learn more: https://bit.ly/3BJvyG7

Its almost time for BioStock Life Science Summit 2024! 👏 ✒ 🗓 Have you signed up? If not, do so TODAY at https://lnkd.in/evGSkHq9 🗓 🖋 🌟 The program is jam-packed with company showcases and thought-provoking insights from industry leaders and expert investors! Three companies that will take the stage to present their groundbreaking work are LIPUM AB, Herantis Pharma Plc. and Vesper Bio. 🌟 Ping Ola Sandborgh, Antti Vuolanto and Lovisa Sunesson 😎

It was full house, when Vesper Bio's CEO Paul Little presented the amazing progress we have done so far 2024 and the future plans for Vesper at #BIOEurope in Stockholm #FTD #neuroscience #danishbiotech

Next week Vesper Bio will be in Stockholm, Sweden, for BIO-Europe 2024 which is taking place from 4-6 November.   Our CEO Paul Little will deliver a company presentation and our Director of Business Development Lovisa Sunesson will also be in attendance.   📅Monday, 4 November |🕔14:00 - 14:15 CET |📍Room K18   Make sure to come along to this presentation to learn more about our pioneering work in #sortilin biology - including our lead candidate #VES001, a first-in-class, oral, small molecule sortilin inhibitor for the treatment of frontotemporal dementia (#FTD).   Contact us on partneringONE, or reach out directly, if you would like to meet Paul or Lovisa.   #BioEurope2024 #innovation #partnering

Introducing Vesper Bio's Senior Vice President of Operations, Lisbet Wreghitt 🎉 #MeetTheTeam   Since joining us in June 2023, Lisbet has played a key role in strategic planning and decision-making - all while promoting the growth and development of our talented team.   We’re proud to have her leadership as we advance our groundbreaking pipeline of first-in-class small molecule #sortilin inhibitors for treating neurodegenerative diseases, including our lead candidate #VES001 for frontotemporal dementia (FTD).   #FTD #Operations #Strategy

Vesper Bio CEO Paul Little and Director of Business Development Lovisa Sunesson will be attending the LSX Nordic Congress in Copenhagen this week! The Congress showcases the leaders in Nordic life science innovation to accelerate investment and facilitate partnering relationships. If you are also in attendance, please get in touch to find out more about Vesper Bio, as we look to advance our lead candidate #VES001, a first-in-class oral, brain penetrant, small molecule sortilin inhibitor for the treatment of frontotemporal dementia (#FTD), into Phase 2 clinical trials. #sortilin #LSXNordic #biotech